Annual ROE
-39.04%
+33.80%+46.40%
December 31, 2023
Summary
- As of February 8, 2025, EYPT annual return on equity is -39.04%, with the most recent change of +33.80% (+46.40%) on December 31, 2023.
- During the last 3 years, EYPT annual ROE has risen by +298.83% (+88.45%).
- EYPT annual ROE is now -217.77% below its all-time high of 33.15%, reached on June 30, 2015.
Performance
EYPT ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-50.67%
-0.22%-0.44%
September 30, 2024
Summary
- As of February 8, 2025, EYPT quarterly return on equity is -50.67%, with the most recent change of -0.22% (-0.44%) on September 30, 2024.
- Over the past year, EYPT quarterly ROE has increased by +66.60% (+56.79%).
- EYPT quarterly ROE is now -189.19% below its all-time high of 56.81%, reached on September 30, 2014.
Performance
EYPT Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
EYPT ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +46.4% | +56.8% |
| 3 y3 years | +88.5% | +27.1% |
| 5 y5 years | +78.5% | +27.1% |
EYPT ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +46.4% | -0.6% | +56.8% |
| 5 y | 5-year | at high | +88.5% | -0.6% | +87.7% |
| alltime | all time | -217.8% | +90.8% | -189.2% | +90.1% |
EyePoint Pharmaceuticals ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -50.67%(+0.4%) |
| Jun 2024 | - | -50.45%(-9.1%) |
| Mar 2024 | - | -55.53%(-12.6%) |
| Dec 2023 | -39.04%(-46.4%) | -63.55%(-45.8%) |
| Sep 2023 | - | -117.27%(+15.0%) |
| Jun 2023 | - | -101.93%(+25.2%) |
| Mar 2023 | - | -81.39%(+17.1%) |
| Dec 2022 | -72.84%(+26.5%) | -69.53%(+30.1%) |
| Sep 2022 | - | -53.46%(-1.9%) |
| Jun 2022 | - | -54.48%(+8.2%) |
| Mar 2022 | - | -50.35%(-10.7%) |
| Dec 2021 | -57.58%(-83.0%) | -56.36%(-29.3%) |
| Sep 2021 | - | -79.74%(-3.0%) |
| Jun 2021 | - | -82.17%(-40.0%) |
| Mar 2021 | - | -136.92%(-66.7%) |
| Dec 2020 | -337.87%(+36.7%) | -411.72%(+7.2%) |
| Sep 2020 | - | -383.97%(+7.6%) |
| Jun 2020 | - | -356.72%(+24.9%) |
| Mar 2020 | - | -285.54%(+20.7%) |
| Dec 2019 | -247.12%(+36.3%) | -236.52%(-26.6%) |
| Sep 2019 | - | -322.12%(-24.2%) |
| Jun 2019 | - | -424.85%(-11.8%) |
| Mar 2019 | - | -481.50%(+3.7%) |
| Dec 2018 | -181.35%(-57.3%) | - |
| Sep 2018 | - | -464.26%(-9.0%) |
| Jun 2018 | -424.98%(+293.3%) | -510.01%(+117.3%) |
| Mar 2018 | - | -234.74%(+21.4%) |
| Dec 2017 | - | -193.41%(+43.2%) |
| Sep 2017 | - | -135.08%(+11.0%) |
| Jun 2017 | -108.05%(+10.9%) | -121.71%(+15.7%) |
| Mar 2017 | - | -105.19%(+2.7%) |
| Dec 2016 | - | -102.43%(-18.0%) |
| Sep 2016 | - | -124.97%(+20.7%) |
| Jun 2016 | -97.39%(-393.8%) | -103.54%(+13.2%) |
| Mar 2016 | - | -91.46%(+5.4%) |
| Dec 2015 | - | -86.79%(+25.2%) |
| Sep 2015 | - | -69.33%(-393.3%) |
| Jun 2015 | 33.15%(-128.1%) | 23.64%(-18.8%) |
| Mar 2015 | - | 29.13%(-35.8%) |
| Dec 2014 | - | 45.36%(-20.2%) |
| Sep 2014 | - | 56.81%(-157.7%) |
| Jun 2014 | -118.06% | -98.48%(-5.3%) |
| Mar 2014 | - | -103.98%(-11.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | - | -116.99%(+13.4%) |
| Sep 2013 | - | -103.21%(+8.5%) |
| Jun 2013 | -111.55%(+14.7%) | -95.12%(+31.1%) |
| Mar 2013 | - | -72.54%(+10.5%) |
| Dec 2012 | - | -65.67%(-48.2%) |
| Sep 2012 | - | -126.85%(+22.2%) |
| Jun 2012 | -97.26%(+297.1%) | -103.78%(+30.7%) |
| Mar 2012 | - | -79.41%(+10.9%) |
| Dec 2011 | - | -71.62%(+213.3%) |
| Sep 2011 | - | -22.86%(-16.2%) |
| Jun 2011 | -24.49%(-179.2%) | -27.28%(-270.4%) |
| Mar 2011 | - | 16.01%(-2.1%) |
| Dec 2010 | - | 16.36%(-42.2%) |
| Sep 2010 | - | 28.32%(-22.2%) |
| Jun 2010 | 30.94%(-430.2%) | 36.41%(-262.4%) |
| Mar 2010 | - | -22.42%(+77.8%) |
| Dec 2009 | - | -12.61%(-19.9%) |
| Sep 2009 | - | -15.74%(+55.2%) |
| Jun 2009 | -9.37%(-93.0%) | -10.14%(-94.1%) |
| Mar 2009 | - | -173.02%(+29.2%) |
| Dec 2008 | - | -133.87%(+21.8%) |
| Sep 2008 | - | -109.92%(+15.9%) |
| Jun 2008 | -133.19%(+37.2%) | -94.83%(+223.2%) |
| Mar 2008 | - | -29.34%(-2.8%) |
| Dec 2007 | - | -30.19%(-20.5%) |
| Sep 2007 | - | -37.97%(-679.7%) |
| Jun 2007 | -97.11%(+342.2%) | 6.55%(-54.8%) |
| Mar 2007 | - | 14.48%(-51.8%) |
| Dec 2006 | - | 30.05%(+76.5%) |
| Sep 2006 | - | 17.03%(-144.0%) |
| Jun 2006 | -21.96%(-24.9%) | -38.71%(+8.5%) |
| Mar 2006 | - | -35.67%(+14.7%) |
| Dec 2005 | - | -31.09%(+18.2%) |
| Sep 2005 | - | -26.31%(-36.4%) |
| Jun 2005 | -29.24%(+76.7%) | -41.36%(+19.6%) |
| Mar 2005 | - | -34.57%(+32.0%) |
| Dec 2004 | - | -26.19%(+48.2%) |
| Sep 2004 | - | -17.67%(+82.9%) |
| Jun 2004 | -16.55%(-60.8%) | -9.66%(-84.9%) |
| Mar 2004 | - | -64.13%(+12.2%) |
| Dec 2003 | - | -57.17%(+15.0%) |
| Sep 2003 | - | -49.72%(+14.1%) |
| Jun 2003 | -42.19%(+344.1%) | -43.59% |
| Jun 2001 | -9.50% | - |
FAQ
- What is EyePoint Pharmaceuticals annual return on equity?
- What is the all time high annual ROE for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual ROE year-on-year change?
- What is EyePoint Pharmaceuticals quarterly return on equity?
- What is the all time high quarterly ROE for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly ROE year-on-year change?
What is EyePoint Pharmaceuticals annual return on equity?
The current annual ROE of EYPT is -39.04%
What is the all time high annual ROE for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual return on equity is 33.15%
What is EyePoint Pharmaceuticals annual ROE year-on-year change?
Over the past year, EYPT annual return on equity has changed by +33.80% (+46.40%)
What is EyePoint Pharmaceuticals quarterly return on equity?
The current quarterly ROE of EYPT is -50.67%
What is the all time high quarterly ROE for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly return on equity is 56.81%
What is EyePoint Pharmaceuticals quarterly ROE year-on-year change?
Over the past year, EYPT quarterly return on equity has changed by +66.60% (+56.79%)